Novo Nordisk to acquire ocedurenone for uncontrolled hypertension from KBP Biosciences

Bagsværd, Denmark and Singapore, 16 October 2023 – Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to 1.3 billion US dollars. Ocedurenone is an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist (nsMRA) that is currently being examined in the phase 3 trial CLARION-CKD in

Related Keywords

United States ,Singapore ,Denmark ,Fred Yang ,Martin Holst Lange ,Novo Nordisk ,Zhenhua Huang ,Camilla Sylvest ,Goodwin Procter ,Covington Burling ,Linkedin ,Youtube ,European Society Of Hypertension ,Facebook ,European Society Of Cardiology ,Development At Novo Nordisk ,World Health Organization ,Biosciences Pte Ltd ,Strategy Corporate Affairs At Novo Nordisk ,Commercial Strategy ,Corporate Affairs ,Blood Pressure ,Advanced Chronic Kidney Disease ,Health Organization ,Task Force ,European Society ,Practice Guideline ,Chronic Kidney Disease ,Systolic Blood Pressure ,Kidney Disease ,Cardiovascular Events ,Bp ,Mineralocorticoid Receptor ,Hypertension ,Larion Ckd ,